Lung function normalization with indacaterol/glycopyrronium/mometasone furoate in patients with asthma

K. Chapman (Toronto, Canada), H. Watz (Grosshansdorf, Germany), J. Beier (Wiesbaden, Germany), D. Singh (Manchester, United Kingdom), J. Hohlfeld (Hannover, Germany), Z. Diamant (Lund, Sweden), V. Scholz (Berlin, Germany), A. Sarkar (Oberhaching, Germany), I. Jones (Basel, Switzerland), R. Li (Beijing, China), P. Pinot (Basel, Switzerland), H. Tillmann (Basel, Switzerland)

Source: International Congress 2019 – Clinical studies of asthma treatments

Session: Clinical studies of asthma treatments
Session type: Thematic Poster
Number: 2539

Disease area: Airway diseases

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
K. Chapman (Toronto, Canada), H. Watz (Grosshansdorf, Germany), J. Beier (Wiesbaden, Germany), D. Singh (Manchester, United Kingdom), J. Hohlfeld (Hannover, Germany), Z. Diamant (Lund, Sweden), V. Scholz (Berlin, Germany), A. Sarkar (Oberhaching, Germany), I. Jones (Basel, Switzerland), R. Li (Beijing, China), P. Pinot (Basel, Switzerland), H. Tillmann (Basel, Switzerland). Lung function normalization with indacaterol/glycopyrronium/mometasone furoate in patients with asthma. 2539

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.